Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HX009 in Chinese Patients With Relapsed/Refractory Lymphoma
NCT05189093Phase 2Completed
- Sponsor
- Hanx Biopharmaceuticals
- Start
- Dec 2021
- Primary completion
- Jun 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of HX009 in lymphoma, sponsored by Hanx Biopharmaceuticals. Started Dec 2021; status: completed.
02
Drugs
HX009
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT05189093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05189093.